Shamburg News · 8-K filed Nov 13, 2026, 8:10 AM EST

Biofrontera Reports Q3 2026 Net Product Revenue of $9.1 Million, Up 29.8% Year Over Year

BFRI · Biofrontera Inc.

  • Earnings
  • Materiality: high

Biofrontera Inc. reported net product revenue of $9.1 million for the quarter ended September 30, 2026, an increase of 29.8% from $7.0 million a year earlier. The company reported a net loss of $6.4 million, or $(0.42) per share, compared with a net loss of $6.6 million, or $(0.62) per share, in the prior-year quarter. Adjusted EBITDA was $(5.5) million compared with $(6.0) million a year earlier. The press release also noted FDA approval of Ameluz for superficial basal cell carcinoma on September 9, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001493152-26-051546.

Written from the filing by Shamburg Markets. Figures are as reported by the company.